Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Atezolizumab for locally advanced or metastatic PD-L1-selected NSCLC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 30.09.15
Views: 3806

Dr Benjamin Besse - Institut Gustave Roussy, Villejuif, France

Dr Besse talks to ecancertv at ECC 2015 about the phase II, single-arm BIRCH trial of atezolizumab as first-line or subsequent therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours express PD-L1.

Results showed that atezolizumab has clinically meaningful efficacy as monotherapy in patients with PD-L1-selected, advanced NSCLC with no unexpected toxicities and suggest that PD-L1 selection may provide a way to identify patients most likely to benefit from treatment with this investigational agent.

Read more here

ecancer's filming at ECC 2015 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.


Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation